Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia and shape the next wave of immunomodulating therapies from the company’s BESTech™ platform Palo Alto, Calif., Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today…
Menlo Park, Calif., September 9, 2025 – Nuvig Therapeutics, Inc. (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, today announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors and James Mackay, Ph.D., as Independent Board Chair. “David’s…
NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was well tolerated with no serious or severe adverse events, supporting advancement into Phase 2 development for CIDP Menlo Park, Calif., May 14, 2025 – Nuvig Therapeutics, Inc.,…